UA College of Medicine Phoenix | 2013 Commencement
2013 Commencement UA College of Medicine – Phoenix Fifty University of Arizona College of Medicine -- Phoenix medical students were officially conferred with their medical degrees at ceremonies on May 8 in the third graduation for the downtown Phoenix medical school. Read more: http://phoenixmed.arizona.edu
Convergence and Personalized Medicine
Greg Yap is Senior Vice President and Lifecycle Leader for Advanced Staining Assays at Ventana Medical Systems. In this role, Greg is responsible for Ventana’s 450 million dollar cancer diagnostic testing business. Ventana’s tests are the market leaders and are used to help guide treatment for over 6 million cancer patients each year worldwide. Previously, Greg was Chief Operating Officer at Cellective Dx, a circulating tumor cell company, and held multiple senior operating roles at Affymetrix.
Announcing Grants for Emerging Medical Device Companies
Arizona has one of the fastest growing bioscience communities in the US; annual total economic activity is now $28.8 billion. It has a particularly robust medical device sector, which constitutes 32% of Arizona’s non-hospital bioscience employment. With first-class research institutions and an industry spanning from one-person shops to industry giants, Arizona has it all.To support this critically important sector, the City of Peoria, Arizona, BioAccel and The Plaza Companies have created BioInspire™, an incubator in Peoria dedicated to medical device development that provides working capital and space to qualifying companies. More than just a facility, this collaboration was created to connect the medical device community.
SynCardia Systems, Inc.05/29/2013
Heart of a Champion - Justin Ryder
Former Semi-Pro Arena Football Player and Father of 3 Had Surgery for an Enlarged Heart at Age 18 Justin Ryder has battled heart problems nearly all his adult life. But after multiple surgeries, the 35-year-old Las Vegas, Nev., resident finally has a ticker that works - SynCardia's temporary Total Artificial Heart. Running out of options with his patched-up natural heart, Ryder had an artificial one implanted in early December at the University of Arizona Medical Center. It keeps him going, literally, while he awaits a donor heart.
Ventana Medical Systems, Inc.08/15/2013
VENTANA BenchMark Special Stains automation: manual versus automated time-lapse video
VENTANA BenchMark Special Stains automated slide stainer eliminates manual processes and temperature dependencies with automated deparaffinization and independent slide heating for histology labs upgrading manual processes or current automation systems
SynCardia Systems, Inc.06/13/2013
Getting to the Destination: Dr. Marvin Slepian, SynCardia
Arizona Pioneer Thomas M. Grogan, MD
Thomas M. Grogan, M.D., Founder of Ventana and SVP, Medical Affairs of Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, receives the AZBio Pioneer Award for Lifetime Achievement at the 2013 AZBio Awards on October 10, 2013. Dr. Grogan was a pathologist and professor at the University of Arizona when in the mid 1980’s he and a small team set out to challenge the limitations of the then current standards and processes for cancer pathology. What was to become the company’s first digital pathology instrument evolved from Grogan’s notes on a yellow pad into the BenchMark IHC/ISH staining platforms. Under Grogan’s leadership, Ventana was founded in 1987, went public in 1996, and was acquired by Roche for $3.4 billion in 2008. Over the last 25 years, Ventana has grown to become a global leader in developing and manufacturing tissue-based diagnostic instruments and tests focused on the detection of cancer. Ventana employees continue to pursue the same deeply rooted mission of innovating diagnostic testing and enabling personalized healthcare to improve the lives of all patients afflicted with cancer worldwide. Dr. Grogan has made it his personal mission to make life better for the millions of patients who battle cancer each day. His passion and dedication are infectious and has spread across the company that he and his team built. Through their efforts they have revolutionized the field of cancer diagnostics and are pioneering new roads in the field of personalized healthcare.”